Pharma

  • The HHS in DC
    Image attribution tooltip
    Alex Wong / Staff via Getty Images
    Image attribution tooltip

    HHS announces sweeping reorganization, including cuts of 10K workers

    Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.

    By Rebecca Pifer • March 27, 2025
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images
    Image attribution tooltip

    How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

    After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

    By • March 27, 2025
  • tech clinical trial Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Tech for Clinical Trials

    Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

    By PharmaVoice staff
  • Robert F. Kennedy Jr. stands in front of croded congressional room
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Rx-to-OTC rule gets pushed back — again

    A delay of the prescription-to-OTC rule signals health agencies’ ongoing reluctance to implement new regulations.

    By • March 26, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/PharmaVoice
    Image attribution tooltip

    Biogen plots new global headquarters in Kendall Square

    The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

    By Jacob Bell • March 25, 2025
  • Ruxandra Draghia-Akli
    Image attribution tooltip
    Permission granted by Novavax
    Image attribution tooltip
    Profile

    The industry heavyweight behind Novavax’s push to bounce back

    As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

    By Alexandra Pecci • March 25, 2025
  • Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly, Novo expand DTC reach of obesity meds after compound win

    The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.

    By • March 24, 2025
  • recession
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How pharma could feel the pain of a recession

    Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

    By • March 21, 2025
  • Florida Governor Ron DeSantis speaks at a podium.
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Vaccine makers face mRNA backlash as states seek further restrictions

    A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

    By • March 19, 2025
  • china biotech
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The key factors shaping China’s biopharma boom

    Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

    By Alexandra Pecci • March 19, 2025
  • radioactive syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

    Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

    By Kelly Bilodeau • March 17, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Q&A

    Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

    The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

    By • March 17, 2025
  • Senator Elizabeth Warren speaks during a legislative hearing, holding her handout to the side. A sign in front of her reads "Ms. Warren."
    Image attribution tooltip
    Andrew Harnik / Staff via Getty Images
    Image attribution tooltip

    Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

    HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

    By • March 13, 2025
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Takeda’s $770M deal deepens Big Pharma’s omics push

    The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

    By Alexandra Pecci • March 13, 2025
  • The dome of the U.S. Capitol Building as seen at dawn.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

    Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

    By • March 12, 2025
  • brain design with neuro points scattered
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

    Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

    By • March 11, 2025
  • Colorful medical pills cover Benjamin Franklin's face on one hundred american dollar bill.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pricing transparency is in the spotlight — and that could be good news for drugmakers

    An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

    By • March 11, 2025
  • Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    What’s driving pharma’s layoffs in 2025

    Familiar foes in the industry have claimed a slew of jobs in recent months.

    By • March 10, 2025
  • Trade routes, tariffs
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges

    Experts say cost and other barriers present challenges to returning to U.S. shores.

    By Kelly Bilodeau • March 10, 2025
  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The time is ripe for pharma M&A. Why are drugmakers holding out?

    The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.

    By • March 6, 2025
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    With patent losses on the horizon, Amgen refocuses its business strategy

    The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

    By Alexandra Pecci • March 5, 2025
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie gets into obesity with $350M deal for once-weekly shot

    A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

    By Jonathan Gardner • March 5, 2025
  • Pill pop art
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Americans want to participate in clinical trials — so why don’t they?

    A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

    By Kelly Bilodeau • March 4, 2025
  • GlaxoSmithKline CEO Emma Walmsley
    Image attribution tooltip
    Courtesy of GSK Flickr page
    Image attribution tooltip

    How pharma CEO pay shifted for these 4 companies last year

    Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.

    By • March 3, 2025
  • Teva
    Image attribution tooltip
    Permission granted by Teva
    Image attribution tooltip

    Teva targets schizophrenia to build on innovative medicines growth

    The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

    By • Feb. 28, 2025
  • Ben Taylor, CFO, Recursion Pharmaceuticals
    Image attribution tooltip
    Permission granted by Recursion
    Image attribution tooltip
    Q&A

    AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

    Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

    By • Feb. 27, 2025